Times Square Capital Management, LLC Moon Lake Immunotherapeutics Transaction History

Times Square Capital Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 08, 2024	SELL	$38.43 - $48.6 $220,972 - $279,450	-5,750 Reduced 2.74%	203,737 $8.96 Million
Q1 2024 May 07, 2024	SELL	$43.78 - $63.86 $12.2 Million - $17.8 Million	-279,318 Reduced 57.14%	209,487 $10.5 Million
Q4 2023 Feb 07, 2024	BUY	$36.35 - $63.02 $2.82 Million - $4.89 Million	77,590 Added 18.87%	488,805 $29.5 Million
Q3 2023 Nov 17, 2023	BUY	$48.35 - $61.26 $18.4 Million - $23.4 Million	381,215 Added 1270.72%	411,215 $23.4 Million
Q2 2023 Aug 09, 2023	BUY	$19.01 - $51.79 $570,300 - $1.55 Million	30,000 New	30,000 $1.53 Million

124

58.2M

52.2K

38K

Ticker MLTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,925,600
Market Cap $1.93B
Description
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...

Get notified when there are updates to the investment portfolio of Times Square Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Times Square Capital Management, LLC with notifications on news.